Phase 1 study of Gemcitabine, Cisplatin and S-1 combination chemotherapy in patients with advanced biliary tract cancer
- Conditions
- biliary tract cancer
- Registration Number
- JPRN-UMIN000009536
- Lead Sponsor
- Kitasato University School of Medicine Department of Gastroenterology Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 12
Not provided
1)Simultaneous or metachronous double cancers. 2)Severe complications. 3)The case suspected of infection with feaver. 4)A history of motor paralysis or peripheral neuropathy or edema. 5)Pleural or cardiac effusion requiring treatment. 6)Massive abdominal effusion. 7)Pregnancy or the desire to preserve fecundity. 8)Active lung disease such as interstitial pneumonia or pulmonary fibrosis. 9)Mental disease or psychotic manifestation. 10) A history of serious drug allergy. 11)A history of sever allergic reaction with gemcitabine or cisplatin or S-1. 12)Being treated with other pyrimidine fluoride antineoplastic agents. 13)Being treated with flucytosine. 14)Any patients judged by the investigator to be unfit to participate in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method